{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:07Z","timestamp":1740134887576,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9,14]]},"DOI":"10.1182\/blood-2017-07-797381","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T12:25:17Z","timestamp":1505391917000},"page":"1277-1278","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["High-risk DLBCL: interim PET? Not yet"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-4669","authenticated-orcid":false,"given":"Mark","family":"Hertzberg","sequence":"first","affiliation":[{"name":"PRINCE OF WALES HOSPITAL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2019111904414529100_B1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET\u2013driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111904414529100_B2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111904414529100_B3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111904414529100_B4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"issue":"Supp4","key":"2019111904414529100_B5","article-title":"A randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI2-3) diffuse large B cell lymphoma: rituximab plus dose dense chemotherapy CHOP14\/MegaCHOP14 with or without intensified high dose chemotherapy and autologous stem cell transplantation. Results of DLCL04 trial of Italian Lymphoma Foundation (FIL) [abstract]","volume":"22","author":"Vitolo","year":"2011","journal-title":"Ann Oncol"},{"issue":"27","key":"2019111904414529100_B6","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111904414529100_B7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2019111904414529100_B8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111904414529100_B9","article-title":"Positron emission tomography (PET) guided therapy of aggressive lymphomas\u2014a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial) [abstract]","volume":"124","author":"D\u00fchrsen","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111904414529100_B10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/11\/1277\/1402458\/blood797381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/11\/1277\/1402458\/blood797381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:42:02Z","timestamp":1574138522000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/11\/1277\/36440\/Highrisk-DLBCL-interim-PET-Not-yet"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-797381","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}